ABAB design: I have looked for the primary source twice and failed twice. Either it does not exist or it is somewhere I do not know to look, and I would like to know which.
An ABAB design with a data table and honest limitations — a second dataset posts 91–119
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
A single-person experiment can be genuinely informative if it has a pre-specified outcome, a defined period, and a plan written before the data arrives. Most accounts here have none of those.
It is a small point and it changes the answer, which is an awkward combination.
On ABAB design the community has more anecdote than the confidence in this thread implies, and I include my own contribution in that.
Post #91 answers the question as asked. The question underneath it is different.
ABAB design looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour.
Post #91 put the caveat in the right place and I want to underline it.
Order effects matter. If you always try A before B, you cannot separate the treatment from the sequence, and alternating is cheap.
If anyone can point at the primary source I would be grateful.
Where I would push back on the ABAB design consensus is the confidence, not the direction. The direction looks right. The confidence is borrowed.
Blinding yourself is harder than it sounds and is not impossible. Somebody else preparing labelled containers is the usual approach and it requires a second person you trust.
This has been discussed before and I could not find the thread, so, again.
Where I part company with post #95, and it is a narrow parting.
Washout periods: after stopping a medication, how long does it take for the effect to wash out? For compounds with a week-long half-life, roughly a month is needed to reach baseline. Using that washout period in a before-after design strengthens the inference.
Post #99 is the version of this I will quote in future. One addition.
Filing a mild objection to the consensus on ABAB design. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit.
Multiple outcomes measured without a primary one means something will move. Nominate the primary in advance and report the rest as secondary.
The literature is thinner on this than the confidence in the thread implies.
Reporting the whole series rather than the interesting segment is the discipline that makes personal data worth reading. Selective reporting is the default without effort.
If this contradicts something upthread, the upthread version may well be the better one.
The arithmetic in post #103 is right; the assumption feeding it is the part to check.
Worth separating ABAB design as a question about the compound from ABAB design as a question about the documentation. They get answered by different people and only one of them is answerable here.
Where I part company with post #103, and it is a narrow parting.
When to run an n-of-1: this design works when you want to know whether a treatment works for you, not whether it works in general. For that purpose, it is efficient.
No disagreement from me. Posting only so the question does not look ignored.
I would put moderate confidence on the mainstream reading of ABAB design and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.
Measure the same thing the same way at the same time of day. Most of the noise in personal data is measurement protocol rather than biology.
Confirming post #108 from a second method, which matters more than confirming it from a second person.
Practical note on ABAB design: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would allow.
Building on post #110 rather than restating it.
A single-person experiment can be genuinely informative if it has a pre-specified outcome, a defined period, and a plan written before the data arrives. Most accounts here have none of those.
Post #113 put the caveat in the right place and I want to underline it.
Withdrawal and reintroduction is the strongest design available to an individual, and it only works for effects that reverse on a timescale you can observe.
Taking post #114 at face value and following it one step further.
Expectation effects in an unblinded self-experiment are large and are not a character flaw. Knowing what you expect to find is a reason to design against it.
None of the above is medical advice and I am not qualified to give any.
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
An ABAB design with a data table and honest limitations
An ABAB design with a data table and honest limitations Writing it up because I had to work it out twice and would rather nobody else did. An honest uncertainty about ABAB design rather than a disguised…
|
2 | 45k | 5mo | |
|
About the N-of-1 designs category
Designing a personal experiment that could actually change your mind, including washouts and blinding. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
4 | 22k | 14h | |
|
Designing a personal experiment that could change your mind
Posting this under the heading it deserves: Designing a personal experiment that could change your mind Everything below is what sits behind that. I was wrong about designing a personal experiment in a thread…
|
+2 | 6 | 695 | 6mo |
|
Designing a personal experiment that could change your mind — one year on
Designing a personal experiment that could change your mind — one year on — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on…
|
+74 | 80 | 17k | 2d |
|
Blinding yourself: practical methods and their limits
On the subject in the title: Blinding yourself: practical methods and their limits Working notes rather than a conclusion. A methods question rather than a substantive one, about blinding yourself. Everyone…
|
+40 | 44 | 33k | 5d |
Related topics — sharing the tags confounding, effect size, data table
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: Historical amylin analogues and what happened to them
Second pass at: Historical amylin analogues and what happened to them — setting out what I have, and where I think it stops being reliable. The question about Historical amylin analogues that I actually want…
|
+15 | 19 | 22k | 18mo |
|
Contributing data without breaching anyone's privacy
Contributing data without breaching anyone's privacy Writing it up because I had to work it out twice and would rather nobody else did. Asking about contributing data without breaching directly, because I…
|
+65 | 71 | 839 | 5mo |
|
A claim built entirely on a subgroup analysis — what changed since
On the subject in the title: A claim built entirely on a subgroup analysis — what changed since Working notes rather than a conclusion. What changes if the standard account of claim built is wrong? I ask…
|
2 | 2k | 18mo | |
|
Comparing prices across jurisdictions without misleading yourself
Comparing prices across jurisdictions without misleading yourself — setting out what I have, and where I think it stops being reliable. Working notes on comparing prices across jurisdictions rather than a…
|
+78 | 83 | 33k | 1mo |
|
Follow-up: Subcutaneous absorption kinetics and site differences
Subcutaneous absorption kinetics and site differences — setting out what I have, and where I think it stops being reliable. A follow-up question about Subcutaneous absorption kinetics and site that I did not…
|
4 | 9.9k | 10mo |